Clinical Trials on AMN

Total 942 results

H Scott Boswell
Takeda

Terminated

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

AML | AML, Adult

United States
Technische Universität Dresden
AbbVie

Active, not recruiting

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (RELAX)

Relapsed Adult AML | Refractory AML

Germany
Carbiogene Therapeutics Co. Ltd.
Zhejiang Provincial People's Hospital

Recruiting

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

AML M5 | AML M4

China
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of Quizartinib

Relapsed AML | Refractory AML

Japan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann... and other conditions

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Universal CAR-γδT Cell Injection in the AML Patients

AML

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

AML

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

AML

China
Beijing Immunochina Medical Science & Technology...

Completed

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

AML

China
Stichting Hemato-Oncologie voor Volwassenen Nederland

Withdrawn

Study to Assess an Interphase Cycle With Flotetuzumab. (HOVON162AML)

AML

Netherlands
University of Applied Sciences Upper Austria
Krankenhaus der Barmherzigen Schwestern Ried

Unknown

The Effects of Regular Eye-training With a Mobile Device on Adult Patients With AMD (ETAMD)

AMD

Austria
JW Medical Systems Ltd

Completed

Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent (CREATE)

AMI
Alcon Research

Completed

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

AMD

United States
SwanBio Therapeutics, Inc.

Active, not recruiting

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia (CYGNET)

AMN | AMN Gene Mutation | X-ALD

United States, Netherlands, Germany
National Research Center for Hematology, Russia
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Recruiting

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

AML

Russian Federation
Glycostem Therapeutics BV

Recruiting

Registry of Patients Having Received oNKord®

AML

Switzerland, Germany
Etan Orgel
Astellas Pharma Global Development, Inc.

No longer available

Individual Patient Expanded Access Gilteritinib (ASP2215)

AML

United States
Chinese PLA General Hospital
Navy General Hospital, Beijing

Completed

Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML

AML

China
University Hospital Inselspital, Berne

Withdrawn

Epacadostat, Idarubicin and Cytarabine (EIC) in AML (EIC)

AML

Switzerland
Kanuni Sultan Suleyman Training and Research Hospital

Completed

Serum AMH Levels in Patients Who Underwent Hypogastric Artery Ligation

AMH

Turkey
Alcon Research

Terminated

Anecortave Acetate Risk Reduction Trial (AART)

AMD

India
Turkish Leukemia Study Group

Completed

Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML (TLG-AML-95-002)

AML
Nantes University Hospital
Rennes University Hospital

Not yet recruiting

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (FAR-WEST)

AMD

France
Notal Vision Ltd.

Completed

Retinal Imaging Using NOTAL-OCT V2.5

AMD

Israel
Al Baraka Fertility Hospital

Unknown

AMH and Pregnancy Outcome in IVF

AMH
University Hospital, Caen

Unknown

Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML (IMODLAM)

AML

France
Institute of Hematology & Blood Diseases Hospital

Suspended

Efficacy of Decitabine in Clearance of MRD

AML

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

AML | MDS

United States
Notal Vision Ltd.

Completed

Retinal Imaging Using NOTAL-OCT V3.0

AMD | DR

Israel
Retina Institute of Hawaii

Completed

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD

United States
University Hospital Tuebingen

Recruiting

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML (VenSwitch)

AML | MDS

Germany
Montefiore Medical Center

Recruiting

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

AML | MDS

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

AML | Hyperleukocytosis

Mexico
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
Firalis SA

Active, not recruiting

HeartLinc, a Study With AMI Patients Undergoing PCI (HeartLinc)

AMI Patients

France, Korea, Republic of
Alcon Research

Terminated

Anecortave Acetate Risk-Reduction Trial (AART)

Dry AMD

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML

AML | Elderly
National Cancer Institute (NCI)
The Lymphoma Academic Research Organisation

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

HIV Infection | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin... and other conditions

United States, France
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
Samsung Medical Center
Ministry of Health, Republic of Korea

Recruiting

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Relapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
Ruijin Hospital

Not yet recruiting

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

AML, Adult

China
Abramson Cancer Center at Penn Medicine
Bristol-Myers Squibb

Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance (AGE-ING)

AML, Adult

United States
Rigshospitalet, Denmark

Recruiting

Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial (IDEAL)

AML/MDS

Denmark
GWT-TUD GmbH

Recruiting

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA)

AML | MDS

Germany, Austria
University Hospital Inselspital, Berne

Terminated

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (HDMM)

AML, Adult

Switzerland
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
David Iberri

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults | AML (Adult) With 11q23 (MLL) Abnormalities | AML (Adult) With Del (5q) | AML (Adult) With Inv (16) (p13; q22) | AML (Adult) With t (16;16) (p13; q22) | AML (Adult) With t (8; 21) (q22; q22) and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML

Clinical Trials on AMN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations